About: Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma pneumoniae Community-acquired Pneumonia in Children

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma pneumoniae Community-acquired Pneumonia in Children Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma pneumoniae Community-acquired Pneumonia in Children
Creator	Capaul, Riccarda Berger, Christoph Sauteur, Patrick Van Rossum, Annemarie Bachmann, Lucas Ambroggio, Lilliam Gysin, Claudine Haas, Thorsten Kellenberger, Christian Krautter, Selina Paioni, Paolo Relly, Christa Sauteur, P Seiler, Michelle
Source	Medline; PMC
abstract	BACKGROUND: There are no reliable signs or symptoms that differentiate Mycoplasma pneumoniae (Mp) infection in community-acquired pneumonia (CAP) from other etiologies. Additionally, current diagnostic tests do not reliably distinguish between Mp infection and carriage. We previously determined that the measurement of Mp-specific immunoglobulin M antibody-secreting cells (ASCs) by enzyme-linked immunospot assay allowed for differentiation between infection and carriage. Using this new diagnostic test, we aimed to identify clinical and laboratory features associated with Mp infection. METHODS: This is a prospective cohort study of children, 3–18 years of age, with CAP from 2016 to 2017. Clinical features and biomarkers were compared between Mp-positive and -negative groups by Mann-Whitney U test or Fisher exact test, as appropriate. Area under the receiver operating characteristic curve (AUC) differences and optimal thresholds were determined by using the DeLong test and Youden J statistic, respectively. RESULTS: Of 63 CAP patients, 29 were Mp-positive (46%). Mp positivity was statistically associated with older age (median, 8.6 vs 4.7 years), no underlying disease, family with respiratory symptoms, prior antibiotic treatment, prolonged prodromal respiratory symptoms and fever, and extrapulmonary (skin) manifestations. Lower levels of C-reactive protein, white blood cell count, absolute neutrophil count, and procalcitonin (PCT), specifically PCT <0.25 μg/L, were statistically associated with Mp infection. A combination of age >5 years (AUC = 0.77), prodromal fever and respiratory symptoms >6 days (AUC = 0.79), and PCT <0.25 μg/L (AUC = 0.81) improved diagnostic performance (AUC = 0.90) (P = .05). CONCLUSIONS: A combination of clinical features and biomarkers may aid physicians in identifying patients at high risk for Mp CAP.
has issue date	2019-10-26(xsd:dateTime)
bibo:doi	10.1093/cid/ciz1059
bibo:pmid	31665253
has license	cc-by-nc-nd
sha1sum (hex)	ba367dc0470fd6c7391207b5f46445a370e8e6d8
schema:url	https://doi.org/10.1093/cid/ciz1059
resource representing a document's title	Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma pneumoniae Community-acquired Pneumonia in Children
has PubMed Central identifier	PMC7108170
has PubMed identifier	31665253
schema:publication	Clin Infect Dis
resource representing a document's body	covid:ba367dc0470fd6c7391207b5f46445a370e8e6d8#body_text
is schema:about of	named entity 'ETIOLOGIES' named entity 'ENZYME-LINKED IMMUNOSPOT ASSAY' named entity 'MEASUREMENT' named entity 'LABORATORY' named entity 'TO IDENTIFY' named entity 'SPECIFIC' named entity 'DETERMINED' named entity 'CELLS' named entity 'ALLOWED' named entity 'INFECTIOUS DISEASES' named entity 'BIOMARKERS' covid:arg/ba367dc0470fd6c7391207b5f46445a370e8e6d8 named entity 'CLINICAL FEATURES' named entity 'PNEUMONIA' named entity 'CLINICAL' named entity 'PREDICT' named entity 'HELP' named entity 'USING' named entity 'TO IDENTIFY' named entity 'COMMUNITY-ACQUIRED PNEUMONIA' named entity 'DIAGNOSTICS' named entity 'CLINICAL' named entity '2019' named entity 'IMPROVED' named entity 'MYCOPLASMA PNEUMONIAE' named entity 'MYCOPLASMA PNEUMONIAE' named entity 'SIGNS OR SYMPTOMS' named entity 'DIFFERENTIATION' named entity 'IMMUNOGLOBULIN M ANTIBODY' named entity 'DIAGNOSTIC TESTS' named entity 'BACKGROUND' named entity 'ASSOCIATED WITH' named entity 'CHILDREN' named entity 'PREVIOUSLY' named entity 'DIFFERENTIATE' named entity 'FEATURES' named entity 'INFECTION' named entity 'NEW' named entity 'DO NOT' named entity 'SECRETING' named entity 'RELIABLE' named entity 'DIAGNOSTIC TEST' named entity 'CURRENT' named entity 'diagnostic tests' named entity 'assay' named entity 'infection' named entity 'Clinical Features' named entity 'Community-acquired Pneumonia' named entity 'Mycoplasma pneumoniae' named entity 'epidemiological' named entity 'tested for the presence' named entity 'CAP' named entity 'etiology' named entity 'β-lactam antibiotics' named entity 'biomarkers' named entity 'URT' named entity 'URT' named entity 'Fever' named entity 'clinically defined' named entity 'influenza virus' named entity 'CRP' named entity 'study population' named entity 'R software' named entity 'PCR' named entity 'white blood cell (WBC) count' named entity 'CAP' named entity 'hematology' named entity 'oxygen'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software